Payment overview · 2025
General Payments
$1,173.54
35 reported records · 18 companies
Healthcare provider profile · identity verified
William Y Josephson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTHRIDGE, CA · NPI 1376647651
Verified facts
What the public records show
CMS Open Payments records show William Y Josephson, MD received $1,173.54 in general payments during 2025 across 35 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Entresto, Farxiga, Ingrezza, Jardiance, Linzess, Ozempic, Paxlovid, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lumigan by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $161.67 | 13.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $144.15 | 12.3% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $134.77 | 11.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $122.07 | 10.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.37 | 9.7% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $111.89 | 9.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.55 | 6.3% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.50 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.95 | 3.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.42 | 2.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.81 | 2.4% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $25.07 | 2.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.00 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.93 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.90 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.26 | 1.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.87 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.36 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,173.54 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $161.67 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $134.77 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $122.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $113.37 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $111.89 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $96.24 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $73.55 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.91 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $34.42 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.42 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $33.91 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 133 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 626 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 537 | 86 |
| Metformin Hcl | Metformin Hcl | 430 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 62 |
| Losartan Potassium | Losartan Potassium | 339 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 54 |
| Gabapentin | Gabapentin | 239 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 50 |
| Eliquis | Apixaban | 202 | 35 |
| Furosemide | Furosemide | 192 | 41 |
| Omeprazole | Omeprazole | 192 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 161 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 29 |
| Famotidine | Famotidine | 136 | 27 |
| Lisinopril | Lisinopril | 135 | 28 |
| Carvedilol | Carvedilol | 133 | 25 |
| Farxiga | Dapagliflozin Propanediol | 133 | 25 |
| Januvia | Sitagliptin Phosphate | 130 | 21 |
| Trazodone Hcl | Trazodone Hcl | 127 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 24 |
| Simvastatin | Simvastatin | 119 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 20 |
| Potassium Chloride | Potassium Chloride | 105 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 13 |
| Allopurinol | Allopurinol | 102 | 25 |
| Donepezil Hcl | Donepezil Hcl | 102 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 102 | 36 |
| Alendronate Sodium | Alendronate Sodium | 100 | 26 |
| Propranolol Hcl | Propranolol Hcl | 100 | 11 |
| Vascepa | Icosapent Ethyl | 97 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 18 |
| Ozempic | Semaglutide | 93 | 18 |
| Lorazepam | Lorazepam | 91 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 21 |
| Risperidone | Risperidone | 86 | 11 |
| Benazepril Hcl | Benazepril Hcl | 84 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 22 |
| Jardiance | Empagliflozin | 79 | 20 |
| Mirtazapine | Mirtazapine | 75 | 17 |
| Memantine Hcl | Memantine Hcl | 73 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 22 |
| Finasteride | Finasteride | 61 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 60 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Nylia | Norethindrone-Ethin. Estradiol | 55 | suppressed |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Glimepiride | Glimepiride | 54 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 11 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 52 | suppressed |
| Ibuprofen | Ibuprofen | 51 | 23 |
| Novolog Flexpen | Insulin Aspart | 50 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 49 | 11 |
| Olanzapine | Olanzapine | 49 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 48 | suppressed |
| Clozapine | Clozapine | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 36 |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 14 |
| Alprazolam | Alprazolam | 42 | 13 |
| Celecoxib | Celecoxib | 41 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 12 |
| Kerendia | Finerenone | 40 | suppressed |
| Latanoprost | Latanoprost | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 19 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Austedo | Deutetrabenazine | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Prednisone | Prednisone | 24 | 15 |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 11 |
| Gemtesa | Vibegron | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 16 |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Zoloft | Sertraline Hcl | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Febuxostat | Febuxostat | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Methenamine Mandelate | Methenamine Mandelate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Permethrin | Permethrin | 14 | 14 |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Valium | Diazepam | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,173.54 · 35 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AUSTEDO XR, CAPLYTA, CREON, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, Korlym, LEQVIO, LINZESS, Leqembi, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOWST, Yorvipath, ZENPEP | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error